384 related articles for article (PubMed ID: 11411868)
1. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer.
Horita K; Yamaguchi A; Hirose K; Ishida M; Noriki S; Imamura Y; Fukuda M
Eur J Histochem; 2001; 45(1):73-84. PubMed ID: 11411868
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
3. [C-erbB-2, EGF receptor, p53 and PCNA. The prognostic significance of recent tumor markers for lymph node negative breast cancer].
Schönborn I; Minguillon C; Lichtenegger W; Zschiesche W; Spitzer E
Geburtshilfe Frauenheilkd; 1995 Oct; 55(10):566-71. PubMed ID: 8543129
[TBL] [Abstract][Full Text] [Related]
4. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Factors on the Positivity for Metastases of the Axillary Lymph Nodes from Primary Breast Cancer.
Kondov B; Kondov G; Spirovski Z; Milenkovikj Z; Colanceski R; Petrusevska G; Pesevska M
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Mar; 38(1):81-90. PubMed ID: 28593885
[TBL] [Abstract][Full Text] [Related]
6. Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients.
Gago FE; Tello OM; Diblasi AM; Ciocca DR
J Steroid Biochem Mol Biol; 1998 Dec; 67(5-6):431-7. PubMed ID: 10030692
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
8. Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis.
Ba JL; Liu CG; Jin F
Asian Pac J Cancer Prev; 2014; 15(21):9233-9. PubMed ID: 25422206
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma.
Erdem O; Dursun A; Coşkun U; Günel N
Tumori; 2005; 91(1):46-52. PubMed ID: 15850004
[TBL] [Abstract][Full Text] [Related]
10. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins.
Zhang GJ; Tsuda H; Adachi I; Fukutomi T; Yamamoto H; Hirohashi S
Jpn J Clin Oncol; 1997 Dec; 27(6):371-7. PubMed ID: 9437997
[TBL] [Abstract][Full Text] [Related]
11. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
[TBL] [Abstract][Full Text] [Related]
12. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
Göhring UJ; Scharl A; Ahr A
Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
[TBL] [Abstract][Full Text] [Related]
13. Estrogen and progesterone receptors, c-erbB-2, p53, and Bcl-2 in thirty-three invasive micropapillary breast carcinomas.
Luna-Moré S; de los Santos F; Bretón JJ; Cañadas MA
Pathol Res Pract; 1996 Jan; 192(1):27-32. PubMed ID: 8685038
[TBL] [Abstract][Full Text] [Related]
14. Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein.
Moriki T; Takahashi T; Tanioka F; Yamane T; Hara H
Pathol Res Pract; 1995 Nov; 191(11):1122-32. PubMed ID: 8822114
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the metastasis-inducing protein S100A4 (p9ka) with other prognostic markers in human breast cancer.
Platt-Higgins AM; Renshaw CA; West CR; Winstanley JH; De Silva Rudland S; Barraclough R; Rudland PS
Int J Cancer; 2000 Mar; 89(2):198-208. PubMed ID: 10754500
[TBL] [Abstract][Full Text] [Related]
16. An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis.
Haerslev T; Jacobsen GK
Hum Pathol; 1995 Mar; 26(3):295-301. PubMed ID: 7890281
[TBL] [Abstract][Full Text] [Related]
17. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
18. C-erbB-2 overexpression in primary breast cancer: independent prognostic factor in patients at high risk.
Schönborn I; Zschiesche W; Spitzer E; Minguillon C; Möhner M; Ebeling K; Grosse R
Breast Cancer Res Treat; 1994; 29(3):287-95. PubMed ID: 7914107
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
[TBL] [Abstract][Full Text] [Related]
20. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]